Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Ascendis Pharma A (ASND) over the last 12 years, with Q4 2025 value amounting to -$39.1 million.

  • Ascendis Pharma A's Profit After Tax rose 495.43% to -$39.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$111.3 million, marking a year-over-year increase of 7286.88%. This contributed to the annual value of -$257.7 million for FY2025, which is 16378.46% down from last year.
  • According to the latest figures from Q4 2025, Ascendis Pharma A's Profit After Tax is -$39.1 million, which was up 495.43% from $71.3 million recorded in Q3 2025.
  • Ascendis Pharma A's 5-year Profit After Tax high stood at $140.9 million for Q1 2022, and its period low was -$211.6 million during Q4 2022.
  • Moreover, its 5-year median value for Profit After Tax was -$104.2 million (2025), whereas its average is -$83.6 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Profit After Tax plummeted by 25475.98% in 2021, and later skyrocketed by 16544.77% in 2025.
  • Over the past 5 years, Ascendis Pharma A's Profit After Tax (Quarter) stood at -$121.3 million in 2021, then crashed by 74.41% to -$211.6 million in 2022, then soared by 55.83% to -$93.5 million in 2023, then soared by 56.02% to -$41.1 million in 2024, then increased by 4.95% to -$39.1 million in 2025.
  • Its Profit After Tax was -$39.1 million in Q4 2025, compared to $71.3 million in Q3 2025 and -$44.0 million in Q2 2025.